Jangsoon Lee, Ph.D.

Peer-Reviewed Articles

1. Ha SYY, Anami Y, Yamazaki CM, Xiong W, Haase CM, Olson SD, Lee J, Ueno NT, Zhang N, An Z, Tsuchikama K. An Enzymatically Cleavable Tripeptide Linker for Maximizing the Therapeutic Index of Antibody-Drug Conjugates. Mol Cancer Ther 21(9):1449-61, 2022. PMID: 35793453.
2. Xie X, Lee J, Iwase T, Kai M, Ueno NT. Emerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape. Expert Opin Ther Targets 26(5):405-25, 2022. e-Pub 2022. PMID: 35574694.
3. Masuda H, Harano K, Miura S, Wang Y, Hirota Y, Harada O, Jolly MK, Matsunaga Y, Lim B, Wood AL, Parinyanitikul N, Jin Lee H, Gong G, George JT, Levine H, Lee J, Wang X, Lucci A, Rao A, Schweitzer BL, Lawrence OR, Seitz RS, Morris SW, Hout DR, Nakamura S, Krishnamurthy S, Ueno NT. Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy. JCO Precis Oncol 6:e2000368, 2022. e-Pub 2022. PMID: 35294223.
4. Fong LWR, Lee J, Lin HK, Ueno NT, Zhang S. A gene signature consisting of ubiquitin ligases and deubiquitinating enzymes of SKP2 is associated with clinical outcome in breast cancer. Sci Rep 12(1):2478, 2022. e-Pub 2022. PMID: 35169199.
5. Lim B, Peterson CB, Davis A, Cho E, Pearson T, Liu H, Hwang M, Ueno NT, Lee J. ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells. Biomedicines 9(10), 2021. e-Pub 2021. PMID: 34680527.
6. Su F, Wang X, Pearson T, Lee J, Krishnamurthy S, Ueno NT, Kolonin MG. Ablation of Stromal Cells with a Targeted Proapoptotic Peptide Suppresses Cancer Chemotherapy Resistance and Metastasis. Mol Ther Oncolytics 18:579-586, 2020. e-Pub 2020. PMID: 32995482.
7. Espinosa Fernandez JR, Eckhardt BL, Lee J, Lim B, Pearson T, Seitz RS, Hout DR, Schweitzer BL, Nielsen TJ, Lawrence OR, Wang Y, Rao A, Ueno NT. Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research. PLoS One 15(4):e0231953, 2020. e-Pub 2020. PMID: 32353087.
8. Lee J, Lim B, Pearson T, Choi K, Fuson JA, Bartholomeusz C, Paradiso LJ, Myers T, Tripathy D, Ueno NT. Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. Breast Cancer Res Treat 176(1):251, 2019. PMID: 30982934.
9. Lee J, Lim B, Pearson T, Choi K, Fuson JA, Bartholomeusz C, Paradiso LJ, Myers T, Tripathy D, Ueno NT. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. Breast Cancer Res Treat 175(2):339-351, 2019. e-Pub 2019. PMID: 30826934.
10. Lim B, Murthy RK, Lee J, Jackson SA, Iwase T, Davis DW, Willey JS, Wu J, Shen Y, Tripathy D, Alvarez R, Ibrahim NK, Brewster AM, Barcenas CH, Brown PH, Giordano SH, Moulder SL, Booser DJ, Moscow JA, Piekarz R, Valero V, Ueno NT. A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. Br J Cancer 120(12):1105-1112, 2019. e-Pub 2019. PMID: 31097774.
11. Lee J, Jung ID, Chang WK, Park CG, Cho DY, Shin EY, Seo DW, Kim YK, Lee HW, Han JW, Lee HY. Corrigendum to "p85 beta-PIX is required for cell motility through phosphorylations of focal adhesion kinase and p38 MAP kinase"[Exp. Cell Res. 307(2) (2005) 315-328]. Exp Cell Res 379(2):245-247, 2019. e-Pub 2019. PMID: 30992206.
12. Sato N, Wakabayashi M, Nakatsuji M, Kashiwagura H, Shimoji N, Sakamoto S, Ishida A, Lee J, Lim B, Ueno NT, Ishihara H, Inui T. MEK and PI3K catalytic activity as predictor of the response to molecularly targeted agents in triple-negative breast cancer. Biochem Biophys Res Commun 489(4):484-489, 2017. e-Pub 2017. PMID: 28576487.
13. Torres-Adorno AM, Lee J, Kogawa T, Ordentlich P, Tripathy D, Lim B, Ueno NT. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer. Clin Cancer Res 23(16):4780-4792, 2017. e-Pub 2017. PMID: 28465444.
14. Bartholomeusz C, Xie X, Pitner MK, Kondo K, Dadbin A, Lee J, Saso H, Smith PD, Dalby KN, Ueno NT. MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model. Mol Cancer Ther 14(12):2773-81, 2015. e-Pub 2015. PMID: 26384399.
15. Lee J, Galloway R, Grandjean G, Jacob J, Humphries J, Bartholomeusz C, Goodstal S, Lim B, Bartholomeusz G, Ueno NT, Rao A. Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer. J Cancer 6(12):1306-19, 2015. e-Pub 2015. PMID: 26640591.
16. Xie X, Tang H, Pengliu , Kong Y, Wu M, Xiao X, Yang L, Gao J, Wei W, Lee J, Bartholomeusz C, Ueno NT, Xie X. Development of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer. Cancer Lett 356(2 Pt B):374-381, 2015. e-Pub 2014. PMID: 25304382.
17. Lee J, Bartholomeusz C, Mansour O, Humphries J, Hortobagyi GN, Ordentlich P, Ueno NT. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression. Breast Cancer Res Treat 146(2):259-72, 2014. e-Pub 2014. PMID: 24916181.
18. Sohn J, Liu S, Parinyanitikul N, Lee J, Hortobagyi GN, Mills GB, Ueno NT, Gonzalez-Angulo AM. cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer. J Cancer 5(9):745-53, 2014. e-Pub 2014. PMID: 25368674.
19. Bartholomeusz C, Oishi T, Saso H, Akar U, Liu P, Kondo K, Kazansky A, Krishnamurthy S, Lee J, Esteva FJ, Kigawa J, Ueno NT. MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model. Mol Cancer Ther 11(2):360-9, 2012. e-Pub 2011. PMID: 22144664.
20. Lee J, Ryu SH, Kang SM, Chung WC, Gold KA, Kim ES, Hittelman WN, Ki Hong W, Koo JS. Prevention of bronchial hyperplasia by EGFR pathway inhibitors in an organotypic culture model. Cancer Prev Res (Phila) 4(8):1306-15, 2011. e-Pub 2011. PMID: 21505178.
21. Park SY, Kang JH, Jeong KJ, Lee J, Han JW, Choi WS, Kim YK, Kang J, Park CG, Lee HY. Norepinephrine induces VEGF expression and angiogenesis by a hypoxia-inducible factor-1α protein-dependent mechanism. Int J Cancer 128(10):2306-16, 2011. e-Pub 2010. PMID: 20715173.